A functional cell-based assay was developed using a generic proprietary assay protocol, based on a membrane-potential sensitive dye, for the identification of small-molecule antagonists against the Kv1.3 potassium ion channel. A high-throughput screen (HTS) was subsequently performed with 20,000 compounds from the Evotec library, preselected using known smallmolecule antagonists for both sodium and potassium ion channels. Following data analysis, the hit rate was measured at 1.72%, and subsequent dose-response analysis of selected hits showed a high hit confirmation rate yielding approximately 50 compounds with an apparent IC 50 value lower than 10 µM. Subsequent electrophysiological characterization of selected hits confirmed the initial activity and potency of the identified hits on the Kv1.3 target and also selectivity toward Kv1.3 through measurements on HERG as well as Kv1.3-expressing cell lines. Follow-up structure-activity relationship analysis revealed a variety of different clusters distributed throughout the library as well as several singlicates. In comparison to known Kv1.3 blockers, new chemical entities and scaffolds showing potency and selectivity against the Kv1.3 ion channel were detected. In addition, a screening strategy for ion channel drug discovery HTS, medicinal chemistry, and electrophysiology is presented. (Journal of Biomolecular Screening 2006:57-64) Slack et al. 64 www.sbsonline.org Journal of Biomolecular Screening 11(1); 2006 FIG. 9. Structure-activity relationship (SAR) navigator projection of high-throughput screening (HTS) hits (circles) and literature-known actives (squares). Size indicates potency. Newly identified structural clusters are circled in gray. Singletons are mapped on the border of the projection. Compounds A through D underwent electrophysiology testing.
INTRODUCTION
I ON CHANNELS ARE ONE OF THE MAJOR pharmacological targets for drug design, being involved in a multitude of physiological processes, including the most characterized role in the regulation of cardiac and CNS function and control of the uptake of various metabolites and substrates across the cellular membranes. 1, 2 At present, only a fraction of the now-identified putative ion channel targets has been investigated, and small molecules that interfere with their action have been identified. 3, 4 One relatively well-known candidate, which is currently receiving renewed interest because of its expression profile and involvement in several clinically significant disease modalities, is the Kv1.3 potassium channel.
The voltage-gated potassium channel Kv1.3 was originally identified in human islet cells and T lymphocytes, 5, 6 which, along with the calcium-activated potassium channel (IKCa1), are responsible for the activation of specific subsets of T cells. Specifically, up-regulation and activation of Kv1.3 in activated effector memory T cell populations (T EM ) allow sustained calcium influx into the cell through calcium release-activated channels, leading to the initiation of signaling cascades and gene regulation. Subsequently, the Kv1.3 channel has been identified as a novel potassium conductance within the mitochondria of T lymphocytes. 7 Blockers of the Kv1.3 channel have previously been shown to inhibit this activation and associated proliferation of T EM cells in vivo 8, 9 and are thus of potential use in the treatment of immunemediated diseases, including multiple sclerosis. In addition, recent evidence has extended the regulatory role of Kv1.3 toward glucose metabolism, where deletion of the Kv1.3 encoding gene leads to an increase in glucose uptake in appropriate models. 10 There are currently various peptide species available, showing binding specificity for Kv1.3 over other shaker-related ion channels, which have contributed enormously to our understanding of this target. The relative restricted expression of Kv1.3 in tissue and its apparent pharmacological importance have led to the development and discovery of more appropriate small-molecule inhibitors, including correolide, 11 WIN 17317-3, 12 UK-78282, 13 and, more recently, a series of compounds based on disubstituted cyclohexyls 14 and benzofuran derivates from Ammi visnaga and 5-methoxypsoralen isolated from the plant Ruta graveolens. 15, 16 To isolate new active scaffolds against Kv1.3, we developed a cell-based fluorescent assay in a 384 format applicable for highthroughput screening (HTS). At present, there are only limited technologies available for the functional screening of ion channel activity. [17] [18] [19] These include rubidium flux assays of various forms and ion channel-specific dyes (e.g., Fluo-4 and Aequorin for calcium, SBFI for sodium, and PBFI for potassium). The latter two are seldom used because of low sensitivity. In addition, membranepotential sensitive fluorescent dyes and fluorescence resonance energy transfer (FRET) dye systems are often used to detect the small changes in membrane potential arising from the modulation of ion channel activity. These have the advantage of being applicable to HTS, with a potential throughput of more than a hundred thousand compounds per day. However, all these HTS technologies suffer from differences in sensitivity compared to the gold standard of electrophysiology and are also subject to somewhat higher rates of false-positive and false-negative results, which need and should be taken into consideration when selecting and designing an HTS screening platform. We have developed a modified assay format based on the use of membrane-potential sensitive dyes for the identification of blockers of the Kv1.3 ion channel. This assay format is both sensitive in terms of comparison to electrophysiology and generic, and we have successfully applied this to various voltage-gated potassium and sodium ion channels. This assay was used in a primary screen of 20,000 compounds. With follow-up electrophysiology investigations, genuine activity of compounds on Kv1.3 and specificity over HERG was confirmed. Thus, the screening format and approach presented offer a robust and sensitive method for the detection of ion channel active compounds and scaffolds.
METHODS

Cell culture
A Chinese hamster ovary (CHO) cell line, stably expressing Kv1.3, was previously generated, and expression of Kv1.3 was followed by Western blotting and electrophysiological investigations (data not shown). CHO cells expressing Kv1.3 were maintained and cultivated twice weekly in MEM-alpha medium (Sigma, cat. no. M-8042) supplemented with 10% fetal calf serum (FCS; Sigma, cat. no. F9665) and 1% Pen/Strep (Invitrogen, cat. no. 10378-016). For HTS application, cells were plated into Corning Costar 384 tissue culture plates 24 h prior to screening using a Multidrop (Labsystems). Cells were plated at 10,000 cells per well in a total volume of 75 µL and incubated overnight at 37°C and 5% CO 2 .
Compound selection
A preliminary compound selection was achieved based on previously characterized ion channel active compounds. 3, 4 Using approximately 120 of these structures, a similarity search (> 70% similarity; measured by Tanimoto distance on standard UNITY fingerprints) within the Evotec corporate compound library was performed to isolate whole 384 compound plates with a potentially increased proportion of ion channel-like scaffolds. In total, 60 such plates were selected for screening.
Compound preparation and handling
Compounds were delivered in 384 deep-well polystyrene plates with an intermediate concentration of 60 µM and 2% (v/v) DMSO in assay buffer. For determination of assay robustness and threshold determination during the screen, columns 23 and 24 were filled with buffer supplemented with 2% (v/v) DMSO and 2.5 µM margatoxin. Margatoxin (Alomone Laboratories, Jerusalem, Israel) was resuspended to a final concentration of 10 µM in 0.03% bovine serum albumin (BSA) solution. All compounds were prepared fresh on the day of the screen. Following hit identification, compound integrity was confirmed using high-performance liquid chromatography coupled to mass spectroscopy (LC/ MS).
Membrane potential dye loading and investigation of compound effects
Changes in membrane potential were detected through the use of a membrane-potential sensitive fluorescent dye (FMP; Molecular Devices, cat. no. R8042). The buffer system used was carefully selected to optimize the cell membrane potential and favor conditions where the number of ion channels in the open state would be at a maximum. Using a buffer system with physiological potassium conditions, it was also possible to avoid using subsequent high-concentration potassium buffers to achieve depolarization, the approach often used in rubidium flux and fluorescent imaging plate reader (FLIPR)-based assay formats, which may have detrimental effects on the ion channel pharmacology. 20 The FMP dye was resuspended in 10 mL of assay buffer according to the supplier's protocol. Cell plates were washed using a standard 384 plate washer with assay buffer, incubated with dye, and diluted in assay buffer for 5 min before compound addition to a final concentration of 12 µM. Cell plates were subsequently incubated with compounds for 60 min, after which time the change in fluorescent signal was measured. Each plate received, in addition to compounds, 8 wells of final concentration 500 nM margatoxin and 24 wells of buffer for the determination of assay robustness and threshold setting in columns 23 and 24, respectively. Fluorescent recordings were performed on the Tecan Safire (Tecan, Crailsheim, Germany) using excitation and emission filters of 540 and 555 nm, respectively, and incorporating a bandwidth of 5 nm.
Dose-response analysis and hit confirmation
Selected compounds were picked from the Evotec compound library and diluted over an 11-point dose-response curve using an automated process. Each compound was measured a minimum of 3 times using the same conditions as described above. Automatic fitting routines were subsequently used to define the doseresponse activity and associated IC 50 values.
Electrophysiological investigations
Patch-clamp experiments were performed in the voltage-clamp mode, 21 and whole-cell currents were recorded in (extracellular solution) NaCl 130 mM, KCl 5.4 mM, MgCl 2 1 mM, CaCl 2 1.8 mM, HEPES 10 mM, and glucose 5 mM, pH 7.4, with NaOH. Intracellular solution was KCl 130 mM, HEPES 10 mM, glucose 5 mM, EGTA 1 mM, ATP-Mg 2 mM, and MgCl 2 1 mM, pH 7.2, with KOH.
For investigating effects and reversibility of a test compound on the Kv1.3 potassium channel, CHO cells stably expressing this ion channel were clamped at a holding potential (HP) of -80 mV, hyperpolarized to -90 mV to determine the leak current, and depolarized for 1 s to +40 mV. Pulse-cycling rate was 0.1 Hz. The current after 200 ms of depolarization was analyzed.
For investigating effects and reversibility of a test compound on the HERG potassium channel, CHO cells stably expressing this ion channel were clamped at an HP of -80 mV, hyperpolarized to -90 mV to determine the leak current, depolarized to +20 mV for 1 s, and repolarized to -40 mV for 1 s. Pulse-cycling rate was 0.1 Hz. The current at the end of the pulse to -40 mV was analyzed.
An initial period of 20 stimuli was recorded to determine a biexponential fit of endogenous current rundown. Compound application time was 5 min. After compound application, a washout period of 5 min was recorded.
Data analysis
All active compounds identified in the screen were checked for purity before being analyzed for potential structure-activity relationships. The similarity calculations (Tanimoto distance) used a 2-dimensional fingerprint representation of the structures (standard UNITY fingerprints). 22 Different structural clusters were identified using nonlinear mapping (NLM) 23 in combination with principle component analysis (PCA). The analysis resulted in a 2dimensional projection map (see Fig. 9 ) visualizing qualitatively correct relative similarities between the compounds. Structures in close proximity are considered as 1 chemical cluster. Compounds with no neighbors closer than 70% similarity are projected on the border of the map (singletons). Additional information (activity as size or molecule categories as color) is highlighted. The abovementioned analysis is implemented in the commercially available software SARNavigator by Tripos. For clarity, known literature actives were projected along with the screening hits.
RESULTS AND DISCUSSION
Assay development and validation
A CHO cell line stably expressing the Kv1.3 ion channel was previously established and characterized in electrophysiological measurements (data not shown). Using a modified protocol with a membrane-potential sensitive dye, an assay was developed for the detection of ion channel antagonists. For validation purposes, the reference peptide margatoxin (Alomone Laboratories) with an IC 50 value against Kv1.3 of approximately 200 pM in electrophysiological measurements was used to determine both the sensitivity and robustness of the resulting assay during assay development as well as the subsequent HTS process. Block of Kv1.3 mediated by margatoxin was detected by changes in fluorescence of the membrane-potential sensitive dye measured on the Tecan Safire. Following a short incubation with the dye in order to establish equilibrium within the cell, compounds were added and the cells subsequently incubated under specific buffer conditions for a period of 1 h, thus representing a nonkinetic endpoint assay. Under the final assay conditions selected, the effects of nonspecific membrane transport systems, which would otherwise lead to a decrease in fluorescence signal over the period of the incubation, are reduced, leading to an increased signal to background. In addition, the buffer and assay conditions selected produced good sensitivity in comparison to electrophysiology. Following addition of margatoxin, a relative change in fluorescence of approximately 300%, as compared to wells receiving buffer only, was observed corresponding to a Z′ factor value 24 of greater than 0.6 over the 384-well plate. The measured IC 50 value of approximately 1 nM (Fig. 1) is close to electrophysiological recordings and fits very well to published data using membrane-potential measurements in T lymphocytes. 25 The small discrepancy measured here is likely due to the hydrophobic nature of the reference peptide used and solubility issues in the assay buffer. Only minimal concentrations of BSA, due to undesirable dye interactions, could be used to support solubility of the peptide and prevent nonspecific binding to compound plates and tips. Additional experiments were designed and performed to address the stability of the assay over a period of several hours, DSMO sensitivity, and reagent issues. The assay tolerated up to 1% DMSO, with no apparent loss in either sensitivity or robustness over time. The assay was thus well suited to HTS being sensitive to compound detection, with suitable stability necessary for a prolonged screening program.
HTS analysis of 20,000 compounds against Kv1.3
The parameters established and characterized during assay development were adapted to the screening machines such that the same assay quality was achieved under HTS conditions to that previously observed. Addition of compounds to the fluorescent readout was fully automated for the 384-well format assay. Screening conditions were also optimized to maintain the 1-h incubation period necessary for optimal readout. Under the final automated conditions, a throughput of 20,000 compounds per day was achieved. Based on compound selection, approximately sixty 384-well format plates were analyzed in fully automatic mode. All cell plates were measured on the Tecan Safire, integrated into the HTS platform, after incubation with the compounds as previously described. Statistical analysis of each plate was subsequently performed to ensure that the statistical criteria were fulfilled (Fig. 2) . Primarily, cell plates were assessed for robustness using the incorporated negative and positive control wells on each plate as well as for drifts and plate artifacts that would otherwise lead to a false hit rate. Plates failing to meet quality criteria (Z′ > 0.4; plate uniformity) were automatically scheduled for retesting. Following the completion of the screen, all plates were reanalyzed and the mean Z′ value of the assay measured at 0.6 ( Fig. 3) , which represents excellent overall performance throughout the screen.
A hit threshold was ultimately defined based on the standard deviation of the negative controls on each plate. The mean of all plate thresholds was used to determine a global threshold and found to be at 5.56% inhibition relative to the margatoxin control ( Fig. 4) . Using this inhibition level, a total of 336 compounds were identified as hits. Of the 336 compounds identified, 331 were subsequently tested in 11-point dose-response curves. All compounds were automatically processed and diluted on 384 plates to maintain a uniform DMSO concentration. Again, the last 2 columns were reserved for internal controls to ensure data quality. All compounds were retested under screening concentrations multiple times to aid later data fitting and evaluation. Subsequent data analysis was fully automatic with dose-response curve-fitting generation and IC 50 determination. Figure 5 gives a summary of the doseresponse curves and their distributions among the 331 isolated compounds. In total, 142 compounds identified in the primary screen as either weakly or borderline active compounds (42.9% of all compounds picked) were inactive in the retest, thus giving a hit confirmation rate of more than 50%. In addition to various compounds that showed a full block of the channel (full-range actives), the majority of active compounds gave sigmoidal fits but did not reach the 100% reference block of margatoxin (medium-range actives). The reason a full block of Kv1.3 is not achieved for the majority of compounds is not known, and such compounds would normally be described as partial antagonists or blockers. However, in the context of ion channels, there are very few partial antagonists, and the reason for a submaximal block is sometimes attribut- able to compounds with inverse voltage dependency properties. It is more likely that the submaximal effect observed here is attributable to solubility issues of certain compounds in the assay buffer because a concentrated intermediate solution of 60 µM is required to achieve the corresponding test concentrations noted above. Automatic fitting of the dose-response curves revealed a variety of potencies ( Table 1 ). In total, 47 compounds blocked Kv1.3, with an apparent IC 50 value between 1 and 10 µM, with an additional compound less than 1 µM ( Table 1) . A large and significant number of compounds showed lower potency.
Electrophysiological characterization of selected compounds
To confirm Kv1.3 activity of compounds identified in the primary HTS, the same cell line as used during the screening program was investigated in electrophysiology. Compounds were selected and tested at 3 different concentrations against Kv1.3 to determine IC 50 values. Figure 6A shows the time course of the current amplitude in Kv1.3-expressing cells during an initial period and following addition of 10 µM compound A. A full block of the Kv1.3-mediated current was observed following addition of 10 µM of compounds A, B, C, and D, all of which had apparent IC 50 values in the fluorescent assay of less than 10 µM ( Table 2 ). In Figure 7 , the IC 50 fit for inhibition values at 3 concentrations of compound A is depicted. IC 50 values obtained from current inhibition values at 3 concentrations (1 µM, 3 µM, 10 µM, n = 3-8 each) are summarized in Table 2 . The data obtained in electrophysiology correspond well to the IC 50 values measured using the primary screening cellbased assay. Additional experiments showed that the current recovered after washout, supporting reversible, extracellular block of Kv1.3 via these compounds (see Fig. 6B ). Standard small-molecule inhibitors of the Kv1.3 ion channel have previously been shown to inhibit a variety of ion channels, 26 and measurements were subsequently made to address issues concerning potential undesirable effects of these compounds on HERG. The HERG ion channel is known to be inhibited by a large number of compounds, and inhibition of this ion channel is a life-threatening side effect also of marketed drugs. 27 Therefore, activity of the identified compounds against the HERG ion channel was investigated to assess compound selectivity. Activity of the selected compounds on the HERG ion channel was investigated at a final concentration of 10 µM. In Figure 8 , the time course of the current amplitude in HERG-expressing cells upon application of 10 µM of compound A is depicted. On average, a very minor current reduction of 12% (n = 3) was observed. Current inhibitions of the selected compounds at 10 µM and their specificity against Kv1.3 are summarized in Table 1 . For all compounds tested, a full block of the Kv1.3 channel could be established at 10 µM, whereas on the HERG-expressing cell line, small effects were evident. The compounds identified with the cell-based fluorescent assay were thus both active and specific for Kv1.3 and showed good correlation in terms of the IC 50 values to the electrophysiological measurements.
Structure-activity relationship
From the primary screen, a variety of compounds were identified that subsequently showed both different levels of potency and efficacy toward Kv1.3. Recently, several publications, based mainly around natural products, have led to the isolation and identification of several new chemical structural subclasses active against Kv1.3, with potencies in the low nanomolar range. To relate these known structures to those hits identified in the screen, structure-activity studies were initiated. Initially, those compounds identified from the screen with IC 50 values less than 10 µM were clustered based on their chemical similarities. From the analysis, 10 distinct clusters were identified ( Fig. 9) from the Evotec compound library. These were quite distinct to each other and contained unrelated scaffolds. In addition, numerous singlicates, which could not be associated to any of the clusters, were also ing 3 of the compounds tested in the electrophysiology (compounds B, C, and D). It may be argued that the reported electrophysiological activity of these compounds is thus not surprising, based on this similarity. That compound A, a singlicate, with significant diversity to the other compounds is also relatively potent against Kv1.3 confirms the Kv1.3 activity of the compounds and also shows that a variety of scaffolds and singlicates, considerably diverse to known compounds, have been identified.
SUMMARY
Using an endpoint fluorescent cell-based assay system incorporating a membrane-potential sensitive dye, small-molecule blockers of the Kv1.3 ion channel have been identified. Follow-up dose-response studies identified a variety of highly active compounds whose activity was confirmed in electrophysiological measurements. The reported IC 50 values for these compounds, as measured in the fluorescent assay, are very close to those reported in electrophysiology recordings, confirming the sensitivity of this assay platform. In addition, selectivity of the compounds for Kv1.3 over HERG in electrophysiological investigations could be demonstrated. Follow-up SAR revealed a series of clusters with unique and diverse scaffolds that are significantly different from well-documented Kv1.3 active entities that will no doubt serve as the starting point for chemical optimization attempts around this target. Furthermore, immediate investigations of the hits identified will focus on electrophysiological confirmation of the remaining active compounds and extend the SAR model based on specificity testing of these compounds on other ion channel-expressing cells using automated electrophysiology platforms.
